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Abstract 
Purpose 
Multiple phase II trials of neoadjuvant treatment intensification in locally advanced 
rectal cancer have reported promising efficacy signals but these have not translated 
into improved cancer outcomes in phase III trials. Improvements in phase II trial 
design are needed to reduce these false positive signals. This systematic review 
evaluated the design of phase II trials of neoadjuvant long-course 
(chemo)radiotherapy treatment intensification in locally advanced rectal cancer. 
Methods and Materials 
PubMed, EMBASE, MEDLINE and Cochrane Library were searched for published 
phase II trials of neoadjuvant treatment intensification from 2004-2016. Trial clinical 
design and outcomes were assessed, with statistical design and compliance rated 
using a previously published system. Multivariable meta-regression analysis of 
pathological complete response (pCR) was conducted. 
Results 
Ninety-two eligible trials were identified. Patients with AJCC stage II and III 
equivalent disease were eligible in 87(94.6%) trials. Forty-three(46.7%) trials 
mandated MRI local staging. Only 12(13.0%) trials were randomised, with eight 
having a standard treatment control arm. Just 51(55.4%) trials described their 
statistical design with 21(22.8%) trials failing to report their sample size derivation. 
The majority of trials (n=84, 91.3%) defined a primary endpoint but 15 different 
primary endpoints were used. All trials reported pCR rates. Only 38(41.3%) trials 
adequately reported trial statistical design and compliance. Meta-analysis revealed a 
pooled pCR rate of 17.5%(95%CI:15.7%-19.4%) across treatment arms of 
neoadjuvant long-course (chemo)radiotherapy treatment intensification and 
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substantial heterogeneity amongst the reported effect sizes (I2=55.3%, P<0.001). 
Multivariable meta-regression analysis suggested increased pCR rates with higher 
radiotherapy doses (adjusted p=0.025).  
Conclusions 
Improvement in the design of future phase II rectal cancer trials is urgently required. 
A significant increase in randomised trials is essential to overcome selection bias 
and determine novel schedules suitable for phase III testing. This systematic review 
provides key recommendations to guide future treatment intensification trial design in 
rectal cancer. 
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Introduction 
In rectal cancer, total mesorectal excision (TME) remains the primary curative 
treatment. In operable rectal cancer, phase III randomised trials have demonstrated 
improved local control with neoadjuvant concomitant fluoropyrimidine long-course 
chemoradiotherapy[1, 2] and short-course radiotherapy[3, 4]. Overall 5-year local 
recurrence and disease-free survival rates of 4.7-7.0% and 68.0-73.6% respectively 
are reported, with more recurrences in Stage III disease[2, 3, 5].  
 
Phase II trials play a significant role in identifying experimental regimens showing 
early efficacy signals and acceptable toxicity warranting further testing in definitive 
phase III trials. In the past decade, many phase II trials have focused on neoadjuvant 
treatment intensification of long-course (chemo)radiotherapy in rectal cancer, by 
radiotherapy dose escalation, combination chemotherapy regimens, or the addition 
of biological agents or putative radiosensitisers[6]. So far, promising efficacy signals 
in these phase II trials have not translated into improved cancer outcome in phase III 
trials. Of six phase III trials[7-12] testing the addition of concurrent oxaliplatin to long-
course (chemo)radiotherapy, only one has reported an improvement in disease-free 
survival in peer-reviewed publication. However, the trials reported a 3-21% absolute 
increase in grade 3/4 toxicity. 
 
This systemic review aims to assess the clinical and statistical design of phase II 
rectal cancer trials of neoadjuvant long-course (chemo)radiotherapy treatment 
intensification to better understand where improvements can be made. A meta-
regression analysis explored the effect of clinical design factors on the commonly 
used early efficacy endpoint of pathological complete response (pCR).  
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Methods and Materials 
Search strategy 
This systematic review was conducted in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) group guidelines[13]. 
 
Search terms included all synonyms for phase II trials, rectal cancer, neoadjuvant 
(chemo)radiotherapy and response outcomes. Further details are provided in the 
Appendix. The PubMed, EMBASE, MEDLINE and the Cochrane Library databases 
were searched. Retrieved articles reference lists were reviewed for additional 
articles. 
 
Eligible trials were defined as peer-reviewed publications of phase II trials in rectal 
adenocarcinoma involving neoadjuvant long-course (chemo)radiotherapy treatment 
intensification (either radiotherapy dose, additional chemotherapy or biological 
agents, or radiosensitisers) with reported outcome measures (i.e. pathological 
response, survival or toxicity); written in the English language, between 1st January 
2004 and 3rd August 2016 (the last search date). Updated data in later publications 
of the same cohort were included. Long-course radiotherapy was defined as 
radiotherapy treatment time of at least two weeks and with a radiotherapy equivalent 
dose in 2Gy fractions (EQD2) of 40Gy or greater. Exclusion criteria were conference 
abstracts; retrospective series, case reports or epidemiological trials; phase I or 
phase I/II trials; radiotherapy EQD2 less than 40Gy; and recurrent or metastatic 
disease. Trials with reduced radiotherapy doses, including the use of short-course 
radiotherapy schedules, were excluded to try to reduce trial treatment heterogeneity 
with a focus on the intensification of chemo-radiotherapy treatment. 
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Data extraction and full text analysis 
Trial eligibility criteria, treatment protocols, statistical design, outcomes, and the 
authors’ overall conclusion of the trial results were recorded for each publication 
where available. The authors’ final conclusion was subjectively inferred to be 
negative by the Reviewers (MT and LM) if the authors concluded that the 
experimental regimen was detrimental or had no added benefit; neutral if no 
conclusion was stated; and positive if the agent was concluded to be efficacious with 
acceptable toxicity or worthy of further investigation. The Reviewer’s critical appraisal 
of the statistical design, protocol compliance and interpretation of results was 
recorded (as defined by Mariani & Marubini[14]). The first Reviewer evaluated all 
articles, with 20% of articles verified by the second Reviewer. 
Statistical methods 
Standard treatment dosing 
As there remains no international consensus on standard chemoradiotherapy 
dosing, “standard” treatment dosing was based on control arm doses used in phase 
III trials opened prior to 2004[3, 5, 15] defined as a radiotherapy EQD2 dose of 44 to 
54 Gy (α/β=11.1Gy[16]) with concurrent 5-fluorouracil (200-300mg/m2 daily, days of 
radiotherapy or weekly; or 350-500mg/m2 daily over 5 days, weeks 1 and 5 of 
radiotherapy), or capecitabine (≥1600mg/m2 taken daily or on days of radiotherapy) 
chemotherapy. EQD2 calculations included endorectal intracavitary brachytherapy 
boosts but excluded intraoperative radiotherapy boosts. For non-standard 
fractionation schedules, a tumour repopulation dose increment of 0.15Gy/day[16] 
was used relative to a conventional 25 fraction (5-week) course. 
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Meta-analysis 
A meta-analysis was conducted to estimate the pooled pCR rate, across treatment 
arms of neoadjuvant long-course (chemo)radiotherapy treatment intensification. A 
meta-regression analysis was not performed for long-term outcomes due to variable 
reporting of these end-points. For this analysis, pCR was defined as ypT0ypN0 or if 
not stated, the trial-defined pCR. A random-effects model[17] was used to derive a 
pooled estimate of the pCR rate and 95% confidence intervals (CIs). Cochran’s Q-
test and Higgin’s I2 statistic were used to assess heterogeneity across reported 
effect sizes. A multivariable meta-regression analysis was used to explore the effect 
of pre-specified clinical design factors on the observed heterogeneity, and the pooled 
treatment effect estimate.  The clinical design factors investigated included: single vs 
multi-centre studies, compromise of standard concurrent fluoropyrimidine 
chemotherapy dose (yes vs. no), recommended minimum interval from end of 
(chemo)radiotherapy to surgery (≥6 vs. <6 weeks), radiotherapy EQD2 dose, 
addition of a second concurrent chemotherapy agent (yes vs. no) and addition of 
chemotherapy before or after (chemo)radiotherapy (yes vs. no). Multiple testing was 
adjusted for using a permutation test[18]. All statistical analyses were conducted at 
the 5% significance level using Stata Release 13 (StataCorp LP, USA). For the 
primary analysis, multi-arm trials which were in the minority in this systematic review, 
were excluded to reduce the between trial heterogeneity. A sensitivity analysis was 
conducted to assess of the effect of including treatment intensification arms from 
multi-arm trials, including ‘study’ as a covariate to account for the correlation 
between treatment arms from the same study.  
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Results 
 
General trial characteristics 
Figure 1 summarises the systematic article search results and reasons for exclusion. 
A total of 92 phase II trials were included in this review[19-110] (Supplementary 
Table 1). Trials were predominantly single-centre studies (n=53, 57.6%) (Table 1). 
The median number of patients recruited per trial was 47 (range: 8-144 patients). 
The median recruitment period was 26.9 months (range: 4.0-104.0 months), 
excluding 12 trials not reporting their recruitment duration. Twenty-three (25%) trials 
reported registration on a clinical trials registry.  
 
Eligibility criteria 
Age inclusion criteria were reported in 74 (80.4%) of the 92 trials. A majority of trials 
accepted a WHO performance status (PS) of 0-2 (n=53, 57.6%). 
 
The local disease staging inclusion criteria were equivalent to American Joint 
Committee on Cancer (AJCC) stage II/III disease for 87(94.6%) trials, with three 
trials limiting trial entry to AJCC stage III disease only (Table 1). One trial included 
patients with “non-metastatic disease at a locally advanced stage that made R0 
resection and sphincter preservation uncertain”[61], and another trial enrolled 
patients with AJC  stage I-III disease[28].  
 
Trans-rectal ultrasound (TRUS) was mandatory or allowed as an alternative to MRI 
in 55(59.8%) trials, of which 21 trials used TRUS only for local tumour staging. Only 
43(46.7%) trials mandated MRI (Table 1) with 11(12.0%) having mesorectal fascia 
involvement as an eligibility criterion. 
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Treatment details and intensification regimens 
Of the 92 trials, 8(8.7%) had a control arm that used a “standard” radiotherapy dose-
fractionation and fluoropyrimidine regimen (Table 1). From a total of 104 
experimental neoadjuvant treatment arms; 8 arms involved the addition of induction 
chemotherapy; 78 arms involved the intensification of concurrent chemoradiotherapy 
treatment only (by intensifying the radiotherapy dose and/or the addition of one or a 
combination of cytotoxic, biological or radiosensitising agent); and 18 arms involved 
both induction chemotherapy and concurrent chemoradiotherapy intensification.  
 
Multiple dose and delivery schedules were used for concurrent chemotherapy 
intensification. For example, 34 treatment arms added oxaliplatin using 15 different 
schedules varying in dose, and number and frequency of cycles. Thirty-five 
experimental arms reduced the concurrent fluoropyrimidine dose (Table 1). 
Disregarding the differences in chemotherapy dose or delivery schedules, there were 
29 different treatment agents/strategies tested involving intensification of induction 
chemotherapy, concurrent chemoradiotherapy or both. 
 
Twenty-three different radiotherapy dose-fractionation schedules were used: eight 
standard fractionation schedules; six accelerated hyperfractionation; four 
hypofractionation; two simultaneous integrated boosts; and three brachytherapy or 
intra-operative radiotherapy boosts. Ninety-three (89.4%) experimental arms used a 
“standard” radiotherapy EQD2 equivalent dose, one arm a lower dose, and 10 arms 
a higher dose. 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 
 
 
9 
The modal recommended interval from the end of radiotherapy to surgery was 6-8 
weeks (range: <1 – 23 weeks). Thirty-seven (40.2%) trials had a recommended 
minimum interval to surgery of under six weeks. Fifty-eight (63.0%) trials reported 
the actual interval to surgery, with an overall trial median of 6.9 weeks (range: 0.9 – 
19.3 weeks). 
 
Statistical design and quality 
Seventy-five (81.5%) of the 92 trials were single-arm trials. Of the 17 multi-arm trials, 
12 were randomised (Table 2), four trials consisted of sequential experimental arms 
and in one trial, treatment allocation was at “physician discretion”[93]. Only 
51(55.4%) trials described their phase II statistical design allowing for sample size 
replication. Twenty-one (22.8%) trials did not describe how their sample size was 
derived.  
 
Eighty-four (91.3%) trials defined a primary endpoint with 61(66.3%) trials using pCR 
rate. The remainder used 14 different primary endpoints broadly grouped into five 
themes: i] pathological response; ii] clinical response; iii] toxicity or treatment 
compliance; iv] R0 resection; and v] longer term outcomes (Table 2). The majority of 
trials (n=66, 71.7%) reported pathological regression grading with about one-third of 
trials using the Dworak tumour regression grading score[111]. 
 
All 92 trials reported pCR rates but only 25(27.2%) reported associated CIs or 
standard errors. Seventy-two (78.2%) trials provided their definition of pCR with 22 
trials explicitly requiring local lymph node complete response. Longer-term endpoints 
(e.g. disease-free survival or overall survival) were reported in 41 trials. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 
 
 
10
 
The authors of 58(63.0%) trials interpreted their results positively. Typical positive 
interpretations were that the experimental agent was “clinically active”, had 
“favourable” response rates, “safe” and “worthy of additional investigation”[50, 62, 
75, 93]. Only 23 (25.0%) trials had a “positive” result meeting their original statistical 
hypothesis. Fifty-two (56.5%) trials had a “good” statistical design rating with the 
remainder failing to report their primary endpoint (N=8), and/or sufficient detail of 
their trial statistical design (N=38) or sample size calculations (N=20) to allow 
verification. Fifty trials (54.3%) had a “good” statistical compliance rating. Statistical 
non-compliance was due to authors’ positive interpretation of results despite not 
achieving pre-stated effect size (N=18), insufficient statistical design details to 
support authors’ conclusions (N=17), or non-compliance with the planned sample 
size (N=7). Only trials having both “good” statistical design and compliance to this 
design were rated “good” overall. Thirty-eight (41.3%) trials had a “good” overall 
statistical design and compliance (Table 2). 
 
Meta-analysis 
A total of 71(77.2%) of the 92 trials were included in the meta-analysis (Appendix: 
Supplementary Table 2) after removing multi-arm trials (n=17) and those with no 
pCR events (n=4). Across single-arm trials of neoadjuvant long-course CRT 
treatment intensification, the pooled estimate of the pCR rate was 17.5% (95%CI: 
15.7%-19.4%) (Figure 2). Higgin’s I2 statistic (the proportion of total variance in pCR 
rates between trials due to heterogeneity) was substantial at 55.3%. Cochran’s Q-
statistic, which tests the null hypothesis that the true treatment effect does not differ 
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between trials, was significant (X2=156.53 (d.f.=70), p<0.001). Both tests indicate 
substantial between trial heterogeneity.  
 
A multivariable meta-regression analysis explored the effect of the clinical design 
factors on the pooled estimate of the treatment effect, and between trial 
heterogeneity (Table 3). After fitting these covariates, Higgin’s I2 statistic was 
reduced to 47.9% (I2res). The proportion of the between-trial variance explained by 
the covariates (adjusted R2) was low at 15.6%. The multivariable meta-regression 
analysis (Table 3) suggests a significant association of higher radiotherapy EQD2 
doses (not accounting for treatment duration) with a greater pCR rate (adjusted 
p=0.025). To assess the robustness of this result, the radiotherapy EQD2 was 
recalculated with a tumour repopulation dose increment to account for treatment 
duration and included in the model. In this model, radiotherapy dose was non-
significant (adjusted p=0.092) and the adjusted R2 value reduced to 6.82%. None of 
the other factors included in the model were shown to be significantly associated 
with pCR rate.  
 
A sensitivity analysis further included 28 treatment intensification arms from 17 multi-
arm trials. The pooled estimate of the pCR rate was concordant with the rate 
observed in the primary analysis (17.9%, 95%CI: 16.1%-19.6%); the estimate of the 
heterogeneity amongst reported effect sizes increased (I2=67.6%, X2=302.41 
(d.f.=98), p<0.001). The results of the meta-regression analysis were consistent with 
the primary analysis suggesting a significant association of higher radiotherapy 
EQD2 doses (not accounting for treatment duration) with a greater pCR rate 
(adjusted p=0.041).  
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A meta-analysis for long-term survival outcomes was not performed as only 42 of 92 
trials provided data on such endpoints, and reporting of these outcomes was 
variable, e.g. loco-regional, disease-free, and/or overall survival were reported over 
seven different time-points (e.g. median survival, 1 to 6-year time-points). 
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Discussion 
Our review highlights many problems in the conduct of treatment intensification 
phase II trials. The large number of single centre (57%) studies, the use of a single 
arm non-randomised design (82%) and the lack of trial registry registration (75%) are 
of particular concern. 
 
Eligibility & staging - Over 90% of reviewed trials include patients with AJCC Stage II 
disease. These patients have a low local recurrence rate (<5%) but a high distant 
recurrence rate (∼20%) with current treatment[3, 4, 112]. The incremental benefit of 
local treatment intensification only (70 of 92 trials reviewed) in this group is likely to 
be very small, and difficult to detect.  
 
Although MRI staging was mandated in 46.7% of trials, only 12% included a 
threatened or involved mesorectal fascia in the definition of their eligible patient 
group. The MERCURY group have demonstrated the accuracy of MRI staging for 
assessing mesorectal fascia involvement and its prognostic value [113, 114]. 
 
Selection & reporting bias – Single centre single arm studies were commonly 
performed. Such studies are prone to significant selection bias and provide limited 
information to inform phase III study design. Single centre trials also tend to report 
larger treatment effects than multi-centre trials [115, 116], although this factor was 
not shown to be significant in our meta-regression analysis. Only 12 trials in this 
review were randomised, of which only eight trials used a standard 
chemoradiotherapy control arm. 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 
 
 
14
In phase II trials, randomised trial designs allow comparison of novel treatment 
strategies for selection of the most promising for further testing[104], or the use of a 
“calibration” control arm[117] to minimise selection bias. Randomised trials also 
allow investigation for predictive biomarkers especially important in newer targeted 
agents. Clinical trials units are central to selecting and administering the most 
effective randomisation design. 
 
A standard treatment control arm provides an important benchmark to establish true 
treatment differences. A 5% estimation error of the control effect size in a single-arm 
phase II trial could triple the false-positive error rate[118]. In trials involving 
combination treatments such as in rectal cancer, standard control arms prevent 
potential false impressions of benefit from improvements in standard care or better 
outcomes from selection biases [119, 120].  
 
Time to surgery – There was a wide range of recommended intervals from the end of 
radiotherapy to surgery (range: <1-23 weeks) with limited evidence of the optimum 
interval. Current interest is whether a longer interval may produce further 
downstaging[121]. Our meta-regression analysis did not detect an association 
between the minimum recommended interval ≥6 vs. <6 weeks) and pCR rate, in 
keeping with the recent GRECCAR-6 trial finding no difference in pCR rates for 7 or 
11 week intervals[122].  
 
Treatment intensification regimens – From the multivariable analysis, the addition of 
a second concurrent chemotherapy agent did not show evidence of improved pCR 
rates. Reassuringly, compromising the concurrent fluoropyrimidine dose to facilitate 
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the addition of an experimental agent did not compromise pCR rates. However, the 
analysis suggests a significant association of higher radiotherapy EQD2 dose and 
higher pCR rates in keeping with radiation dose-response modelling[123]. This result 
should be interpreted with caution, in view of the large between-trial heterogeneity 
and the lack of validation of the radiobiological α/β and repopulation constants used, 
but may warrant investigation in future trials. 
 
Early efficacy endpoint – It is clear that there is no validated surrogate end point for 
long-term cancer outcomes in rectal cancer. However, standardisation of efficacy 
measures are important and should be tailored to the clinical question and the 
patient sub-population studied. For example, in locally advanced rectal cancer where 
chemoradiotherapy is a peri-operative approach, pathological and imaging TRG may 
be more appropriate reporting than pCR. Pathological and MRI-defined TRG was 
prognostic for long term outcome in the MERCURY multicentre study[124, 125]. 
Other approaches being evaluated include the Neoadjuvant Rectal Score[126] and 
tumour cell density[127]. In contrast for an organ preservation trial, complete clinical 
response, colostomy and organ preservation rates should be reported[128]. 
 
For a single arm study, interpretation of pCR results is difficult with the lack of a 
contemporary standard treatment comparator, lack of an agreed pCR definition and 
the small sample size. Randomised studies would mitigate some of these problems. 
The European Rectal Cancer Consensus has also proposed a standardised pCR 
definition for future studies[129]. 
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Trial design quality - Only 41.3% of the trials were rated as having “good” statistical 
design and compliance, with 44.6% and 22.9% of trials failing to report a statistical 
design and their sample size derivation respectively. Reporting of endpoints and 
their precision were variable with only 27.2% reporting CIs or standard errors. These 
are key elements in the reporting of clinical trial results, recommended by 
CONSORT[130]. A previous review of all phase II cancer trials found that positive 
findings were more frequently reported in trials with poor statistical design 
reporting[14]. 
 
Only 25.0% of the trials reported registration in a clinical trial registry. The FDA 
Amendments Act of 2007 mandates phase II trial registration on 
ClinicalTrials.gov[131, 132] to improve the disclosure of study design details, 
summary results reporting and minimise publication bias. A recent ASCO survey has 
demonstrated multiple common difficulties of maintaining clinical trial administrative 
and regulatory compliance throughout trial set-up, conduct and after 
completion[133]. Involvement of a clinical trial unit for all phases of phase II trial 
design, funding, registration, conduct and reporting would ensure the regulatory 
compliance, and reporting and statistical rigour of future trials. 
 
Of the 29 different treatment intensification strategies, only five approaches - tested 
in 40 of the 92 phase II trials in this review - have led to subsequent testing in a 
phase III trial (published or registered on ClinicalTrials.gov (https://clinicaltrials.gov/)): 
i) concurrent oxaliplatin chemo-radiotherapy; ii) concurrent irinotecan chemo-
radiotherapy; iii) radiotherapy dose-escalation via simultaneous integrated boost or 
hyperfractionated accelerated radiotherapy, and iv) induction FOLFOX or XELOX 
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chemotherapy. Only one of the six previously mentioned phase III trials testing the 
addition of concurrent oxaliplatin chemo-radiotherapy[7-12] has so far reported an 
improvement in disease free survival. Recent changes to NCCN guidelines regarding 
the use of neoadjuvant/induction chemotherapy are based only on phase II studies. 
The results of phase III trials are awaited. 
 
This systematic review has several limitations. We restricted our review to published 
phase II trials thus excluding trials only presented in conference abstracts. We 
consider it appropriate to ensure prior peer-review of included trials. However, this 
may potentially exclude trials with negative results. Assessment of statistical quality 
was based purely on the published description thus may not be representative of the 
true trial design, while assessment of the author’s interpretation of their results was 
subjective. The trials evaluated in the meta-analysis were investigating varying forms 
of treatment intensification preventing assessment of any specific regimen. We did 
not evaluate the small number of phase II studies that used short course 
radiotherapy as we chose to evaluate intensification strategies associated with 
chemo-radiotherapy. Baseline tumour staging factors likely to be associated with 
pCR rates (e.g. TNM stage, mesorectal fascia involvement) could not be included in 
the meta-analysis as individual patient data was not available in 78 of 92 trials. In 
addition, as discussed, pCR has mixed utility limitations as an early efficacy measure 
and its definition varied between trials and compliance with the intention-to-treat 
principle in its reporting are unknown. Thus, the estimate of the pooled treatment 
effect, and subsequent meta-regression analysis should be interpreted with caution 
and the results serve for hypothesis generating purposes only. There are very likely 
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to be unknown sources of heterogeneity and biases unaccounted for within the 
analysis. 
 
Possible solutions and recommendations 
Our key trial design recommendations for future phase II trials in rectal cancer are: 
• Careful consideration of eligibility criteria is recommended to ensure inclusion of 
patients most likely to benefit from the type of planned treatment intensification. 
• MRI defined local staging inclusion criteria is strongly encouraged to improve 
patient eligibility, selection, and to allow treatment response assessment. 
• Randomised multi-centre phase II trials with a “standard” treatment comparator 
control arm are strongly recommended. Many efficient phase II designs exist 
[119, 134-136].  
• Appropriately statistically designed and sufficiently powered randomised phase II 
trials. 
• Clinically relevant early efficacy endpoints should be used (e.g. TRG for locally 
advanced tumours; complete clinical response in organ preservation strategies). 
• Clinical trial unit support is recommended for all stages of a phase II trial ensuring 
optimum trial design, statistical rigour, and regulatory compliance. 
  
Our recommendations provide an opportunity to design a smaller number of higher 
quality multi-centre randomised phase II rectal cancer trials shortening the time-
frame for this component of development and improving the likelihood of success of 
future phase III trials.  
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Figure Captions 
 
Figure 1: PRISMA flow diagram of literature search. 
Figure 2: Forest plot of pCR rates and pooled estimate. 
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Table 1: Summary of trial and treatment intensification details 
    
No of studies 
(N=92) % 
General    
Region Europe 47 51.1 
Asia 29 31.5 
North America 15 16.3 
Other 1 1.1 
Numbers of centres Single centre 53 57.6 
Multi-centre 39 42.4 
Patient eligibility criteria 
AJCC stage Stage II/III 87 94.6 
Stage III only 3 3.3 
Not stated 2 2.1 
Local staging 
modality 
MRI mandatory 43 46.7 
MRI optional 23 25.0 
No MRI 25 27.2 
Not stated 1 1.1 
Mesorectal fascia 
involvement 
  
Threatened, Involved or 
'Unresectable' 11 12.0 
Not assessed 81 88.0 
Control arm 
 
 
Standard treatment 
control arm 
Yes 8 8.7 
No 84 91.3 
Treatment intensification No of treatment 
arms (N=104) % 
Addition of induction 
chemotherapy 
Total 27 30.0 
Cytotoxics only 20  
Biological agent only 1 
 Combination 6 
 Chemoradiotherapy 
intensification 
Total 96 92.0 
Addition of cytotoxic 38  
Addition of biologic 19  
Addition of radiosensitiser 3  
Radiotherapy dose-
intensification 15  
Combination of above 21  
Other treatments 
  
Adjuvant 
chemotherapy 
Mandatory 43 41.3 
Optional 18 17.4 
No recommendation 43 41.3 
Standard treatment 
dose compromised 
No compromise in dose 69 65.7 
Fluoropyrimidine compromised 35 33.3 
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Table 2: Trial statistical details and design 
 
    
No of 
studies % 
No of treatment arms 1 75 81.5 
2 14 15.2 
 3 1 1.1 
4 2 2.2 
Randomised Yes 12 13.0 
No 80 87.0 
Statistical design Described 51 55.4 
 Simon 2-stage 23  
 Fleming 1-stage 13  
 Gehan 2-stage 2  
 Othera 6  
 
Not referenced but  
sample size reproducible 
7  
 
Not described 41 44.6 
Sample size calculation Stated 71 77.1 
 Not stated 21 22.9 
Primary endpoint Stated 84 91.3 
 pCR 61  
 
Pathological response/ 
downstaging 
10  
 
Toxicity/ Treatment 
compliance 
5  
 
LRFS/ DFS/ Local control 3  
 R0 resection 3  
 
Clinical response/ 
downstaging 
2  
Not stated 8 8.7 
Regression grading system 
used 
Not used 26 28.2 
Dworak 29 31.5 
TNM downstaging 14 15.2 
Mandard 9 9.8 
JSCCR 3 3.3 
AJCC 3 3.3 
Other 8 8.7 
Author interpretation Positive 58 63.0 
 Neutral 6 6.5 
 Negative 28 30.4 
Overall statistical design 
and compliance quality 
Good 38 41.3 
Poor 54 58.7 
aOther designs used in only one study each (see Supplementary Table 1) 
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Table 3. Multivariable meta-regression analysis for pooled pCR rate 
 
 
Covariate Coefficient SE t p>|t| Adjusted p** 95% CI 
Standard fluoropyrimidine dose compromised  
(Yes vs. No) -0.011 0.021 -0.54 0.592 0.993 -0.053, 0.031 
Recommended minimum interval from the end of 
(chemo)radiotherapy to surgery  
(≥ 6 vs. < 6 weeks) 
0.037 0.022 1.72 0.091 0.389 -0.006, 0.081 
Radiotherapy dose* 0.008 0.003 2.91 0.005 0.025 0.002, 0.013 
Addition of a second concurrent chemotherapy 
agent  
(Yes vs. No) 
0.029 0.026 1.10 0.278 0.830 -0.024, 0.081 
Addition of neoadjuvant chemotherapy before or 
after (chemo)radiotherapy  
(Yes vs. No) 
0.001 0.023 0.06 0.956 1.000 -0.045, 0.047 
Single vs. multi-centre studies -0.002 0.020 -0.08 0.938 1.000 -0.041, 0.038 
*Based on EQD2;  ** Permutations = 20000 
I2res = 47.9%; Adjusted R2 = 15.6%; Model F (6, 58) = 2.08; Prob > F = 0.07 
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926 articles 
identified through 
database search
628 articles after 
duplicates removed
298 duplicates removed
516 articles excluded 
based on irrelevant title, 
abstract or citation:
- 2 excluded involving 
short-course 
radiotherapy
- 24 excluded being a 
Phase I/II trial 
112 articles included 
for full text analysis
5 additional articles 
identified from 
manual review of 
reference sections
117 articles included 
for full text analysis
5 excluded being a 
Phase I/II trial
1 excluded based on 
being a non-rectal 
cancer study
12 excluded based on 
duplicate populations
5 excluded based on no 
radiotherapy or 
radiotherapy EQD2 
<40Gy
2 excluded being a 
clinical trial note with no 
results92 articles included 
for data extraction 
and formal review
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 55.3%, p = 0.000)
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